Go back to landing

Put company on watchlist

Carl Zeiss Meditec AG

ISIN: DE0005313704

WKN: 531370

About

Company Snapshot

New: Activate notification

Be informed about new publications

New: AI Factsheet

Coming soon: Summary of the company message by AI/p>

Carl Zeiss Meditec AG · ISIN: DE0005313704 · Newswire (adhoc)

Country: Deutschland · Primary market: Germany · EQS NID: 1161506

Levermann Score

19 January 2021 09:54AM

Carl Zeiss Meditec AG achieves increase in profit in first quarter 2020/21

DGAP-Ad-hoc: Carl Zeiss Meditec AG / Key word(s): Quarter Results
Carl Zeiss Meditec AG achieves increase in profit in first quarter 2020/21

19-Jan-2021 / 09:54 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

Carl Zeiss Meditec AG achieves increase in profit in first quarter 2020/21

Jena, January 19, 2021

Carl Zeiss Meditec AG (ISIN: DE0005313704) has achieved revenue of EUR 368.9 million in the first quarter of fiscal year 2020/21 (previous year: EUR 369.7 million). This corresponds to a revenue development of -0.2% vs. the past year (after adjustment for currency effects^[1]: +2.6%).

Earnings before interest and taxes (EBIT)^[2] amounted to EUR 73.4 million in the first quarter of fiscal year 2020/21 (previous year: EUR 56.8 million). EBIT margin (EBIT / revenue) was 19.9% (previous year 15.4%). EBIT development benefitted in part from lower sales and marketing expenses compared to the previous year's period. In addition, EBIT includes a one-time gain from the sale of a property in the amount of around EUR 2.4 million in the current period.

Earnings per share (EPS)^[3] amounted to EUR 0.52 (previous year: EUR 0.43).

Full results for the first quarter 2020/21 will be published on February 8, 2021.

During the further course of fiscal year 2020/21, the company expects the recovery in revenue and EBIT to continue compared to the previous year, which had seen a marked impact from the COVID-19 pandemic.

Contact for investors and press
Sebastian Frericks
Head of Investor Relations
Carl Zeiss Meditec AG
Tel.: +49 3641 220-116
E-Mail: investors.meditec@zeiss.com

^[1] Currency-adjusted revenue growth is determined by weighing sales in the comparative period with current instead of actual historical exchange rates.
^[2] Earnings before interest and taxes (also operating profit, EBIT) refers to a key earnings figure within the Carl Zeiss Meditec Group and is calculated in accordance with IFRS standards (see Annual Report 2019/20, p. 78 for reconciliation).
^[3] Earnings per share (also EPS) refers to a key earnings figure within the Carl Zeiss Meditec Group and is calculated according to IFRS standards (see Annual Report 2019/20, p. 78 for reconciliation).

19-Jan-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

Language:	English
Company:	Carl Zeiss Meditec AG
	Göschwitzer Str. 51-52
	07745 Jena, Germany
	Germany
Phone:	+49 (0)3641 220-0
Fax:	+49 (0)3641 220-112
E-mail:	investors.meditec@zeiss.com
Internet:	www.zeiss.de/meditec-ag/ir
ISIN:	DE0005313704
WKN:	531370
Indices:	MDAX, TecDAX
Listed:	Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
EQS News ID:	1161506


End of Announcement	DGAP News Service

1161506 19-Jan-2021 CET/CEST

Research & Analysis

Carl Zeiss Meditec AG achieves increase in profit in first quarter 2020/21

Get your free Demo today